BioSpace News Archive

Nexstim Plc Receives R&D Loan From Business Finland

To enable extensive therapeutic use of the NBT System, the project is a major part of Nexstim’s commercialisation process of its therapeutic products.

January 23, 2018
·
3 min read
BBI Solutions Release: Expanding Global IVD Business Exhibits at the World’s Largest Lab Expo

BBI Solutions is gearing up to attend MEDLAB Middle East in Dubai next month.

January 23, 2018
·
3 min read
Bone Therapeutics SA : Provides Business Outlook and Announces Its Financial Calendar for 2018

The Company started 2018 with EUR 8.4 million in cash.

January 23, 2018
·
5 min read
Policy

AnGes Submits Application for Marketing Approval to PMDA for HGF Gene Therapy for Critical Limb Ischemia

The submission is based on the positive results from the randomized, placebo-controlled phase 3 trial and investigator-led clinical study conducted in Japan.

January 23, 2018
·
2 min read
Biotech Bay

Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18

The data will be presented on Monday, March 12, 2018 at 11:30 a.m. ET.

January 23, 2018
·
4 min read
Drug Development

ChemoCentryx Surges on Early-Stage Pancreatic Cancer Trial Data

The study demonstrated OS of 29% at 18 months with CCX872 and FOLFIRINOX combination therapy in all patients treated.

January 23, 2018
·
7 min read
Biotech Bay

Ultragenyx Announces Proposed Public Offering of Common Stock

The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed.

January 23, 2018
·
4 min read
Genetown

BeiGene Announces Closing of $800M Public Offering

BeiGene intends to use proceeds from the offering for working capital and general corporate purposes, including research and development activities.

January 23, 2018
·
3 min read
BioMidwest

AveXis Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters’ Option to Purchase Additional Shares

The net proceeds to AveXis from the offering, after deducting the underwriting discounts and commissions and other offering expenses payable by AveXis, are estimated to be approximately $431.9 million.

January 23, 2018
·
3 min read
Business

NeoChord Announces a Research Collaboration With the Skirball Center for Innovation at the Cardiovascular Research Foundation

The Cardiovascular Research Foundation is an independent, academically focused nonprofit organization dedicated to improving the survival and quality of life for people with cardiovascular disease through research and education.

January 23, 2018
·
2 min read